Literature DB >> 9138678

Evidence that mechanisms dependent and independent of nitric oxide mediate endothelium-dependent relaxation to bradykinin in human small resistance-like coronary arteries.

B K Kemp1, T M Cocks.   

Abstract

1. The effects of the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (L-NOARG), the NO scavenger, oxyhaemoglobin (HbO) and high extracellular K+ upon endothelium-dependent relaxation to bradykinin were investigated in human isolated small coronary arteries. 2. Endothelium-dependent relaxations to bradykinin were compared in vessels contracted to approximately 50% of their maximum contraction to 124 mM KCl Krebs solution, regardless of treatments, with the thromboxane A2 mimetic, U46619 and acetylcholine. All relaxations were expressed as percentage reversal of the initial level of active force. 3. L-NOARG (100 microM) caused a small but significant, 12% (P < 0.01), decrease in the maximum relaxation (Rmax: 91.5 +/- 5.4%) to bradykinin but did not significantly affect the sensitivity (pEC50: 8.08 +/- 0.17). Increasing the concentration of L-NOARG to 300 microM had no further effect on the pEC50 or Rmax to bradykinin. HbO (20 microM) and a combination of HbO (20 microM) and L-NOARG (100 microM) reduced Rmax to bradykinin by 58% (P < 0.05) and 54% (P < 0.05), respectively. HbO (20 microM) and L-NOARG (100 microM, combined but not HbO (20 microM) alone, caused a significant 11 fold (P < 0.05) decrease in sensitivity to bradykinin. HbO (20 microM) decreased the sensitivity to the endothelium-independent NO donor, S-nitroso-N-acetylpenicillamine (SNAP), approximately 17 fold (P < 0.05). 4. Raising the extracellular concentration of K+ isotonically to 30 mM, reduced the Rmax to bradykinin from 96.6 +/- 3.1% to 43.9 +/- 10.1% (P < 0.01) with no significant change in sensitivity. A combination of HbO, L-NOARG and high K+ (30 mM) abolished the response to bradykinin. High K+ did not change either the sensitivity or maximum relaxation to SNAP. 5. In conclusion, L-NOARG does not completely inhibit endothelial cell NO synthesis in human isolated small coronary arteries. By comparison, HbO appeared to block all the effects of NO in this tissue and revealed that most of the relaxation to bradykinin was due to NO. The non-NO -dependent relaxation to bradykinin in the human isolated small coronary arteries appeared to be mediated by a K(+)-sensitive vasodilator mechanism, possibly endothelium-derived hyperpolarizing factor (EDHF).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138678      PMCID: PMC1564524          DOI: 10.1038/sj.bjp.0700928

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Effect of protease-activated receptor (PAR)-1, -2 and -4-activating peptides, thrombin and trypsin in rat isolated airways.

Authors:  J M Chow; J D Moffatt; T M Cocks
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors.

Authors:  B K Kemp; T M Cocks
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 3.  NO and the vasculature: where does it come from and what does it do?

Authors:  Karen L Andrews; Chris R Triggle; Anthie Ellis
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

4.  Stimulation of bradykinin B2-receptors on endothelial cells induces relaxation and contraction in porcine basilar artery in vitro.

Authors:  A Miyamoto; S Ishiguro; A Nishio
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles.

Authors:  John J McGuire; Morley D Hollenberg; Patricia Andrade-Gordon; Chris R Triggle
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Heterogeneous mechanisms of endothelium-dependent relaxation for thrombin and peptide activators of protease-activated receptor-1 in porcine isolated coronary artery.

Authors:  J R Hamilton; T M Cocks
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 7.  Vascular pharmacology of epoxyeicosatrienoic acids.

Authors:  Sandra L Pfister; Kathryn M Gauthier; William B Campbell
Journal:  Adv Pharmacol       Date:  2010

8.  Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries.

Authors:  N H Buus; U Simonsen; H K Pilegaard; M J Mulvany
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

9.  Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healthy humans.

Authors:  Christopher A DeSouza; Christopher M Clevenger; Jared J Greiner; Derek T Smith; Greta L Hoetzer; Linda F Shapiro; Brian L Stauffer
Journal:  J Physiol       Date:  2002-07-01       Impact factor: 5.182

10.  Enzymatic activation of endothelial protease-activated receptors is dependent on artery diameter in human and porcine isolated coronary arteries.

Authors:  Justin R Hamilton; James D Moffatt; James Tatoulis; Thomas M Cocks
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.